CORRECTION Open Access



Correction: Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy

Yu-An Li^{1†}, Chuan Zhao^{1†}, Jing-Jing Ge¹, Cheng Li¹, Feng-Jun Xue¹, Shao-Pei Qi¹, Chi Zhao¹, Chen-Chen Kong¹ and Jun-Ping Zhang^{1*}

Correction: *BMC Cancer* 24, 754 (2024) https://doi.org/10.1186/s12885-024-12373-9

Following publication of the original article [1], a type-setting error was reported. The equal contribution statement was missing in the published article. YuAn Li and Chuan Zhao are co-first authors.

The original article [1] has been corrected.

Published online: 11 July 2024

References

 Li YA, Zhao C, Ge JJ, et al. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy. BMC Cancer. 2024;24:754. https://doi.org/10.1186/s12885-024-12373-9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

†Yu An Li and Chuan Zhao are co-first authors.

The online version of the original article can be found at https://doi.org/10.1186/s12885-024-12373-9.

*Correspondence: Jun-Ping Zhang doczhjp@mail.ccmu.edu.cn ¹Department of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.